CAM
IMVT icon

Cormorant Asset Management’s Immunovant IMVT Stock Holding History

Cormorant Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,165,000
Closed -$49.1M – 59
2023
Q4 		$49.1M Sell
1,165,000
-60,000
-5% -$2.21M 2.34% 8
2023
Q3 		$47M Buy
1,225,000
+675,000
+123% +$15.3M 2.74% 10
2023
Q2 		$10.4M Buy
+550,000
New +$10.3M 0.58% 38
2023
Q1 		– Sell
-400,000
Closed -$7.1M – 79
2022
Q4 		$7.1M Buy
+400,000
New +$5.04M 0.48% 44
2021
Q2 		– Sell
-337,048
Closed -$5.41M – 113
2021
Q1 		$5.41M Sell
337,048
-1,225,904
-78% -$32.3M 0.12% 91
2020
Q4 		$72.2M Sell
1,562,952
-74,999
-5% -$3.47M 1.72% 20
2020
Q3 		$57.6M Buy
+1,637,951
New +$49.3M 2.22% 11

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Cormorant Asset Management's IMVT Position: Q1 2024 in Review

Cormorant Asset Management sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 1,165,000 shares — an estimated $49.1M sold.

Cormorant Asset Management first reported a position in IMVT in Q3 2020 and held it in 7 quarters. The position peaked at $72.2M in Q4 2020. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • Cormorant Asset Management reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
  • Cormorant Asset Management sold 1,165,000 Immunovant shares in Q1 2024, an estimated $49.1M.
  • Cormorant Asset Management first reported a position in Immunovant in Q3 2020 and held it in 7 quarters.
  • Cormorant Asset Management's Immunovant position peaked at $72.2M in Q4 2020.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Cormorant Asset Management's 13F filing for Q1 2024, filed 15 May 2024.